LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication...
Hence then, the article about hansa biopharma announces first commercial kidney transplant patient treated with idefirix in australia was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia )
Also on site :
- Child Psychologists Are Begging Parents and Grandparents To Stop Asking Kids This Question (and What To Ask Instead)
- Ousted L3Harris CEO Chris Kubasik forfeits $45 million—but he’ll still walk away with $80 million in stock and options
- ‘Dancing with the Stars: The Next Pro’: Witney Carson Arrives to Judge a Brutal Coaching Challenge — See Who Went Home